newsfilter
← Latest News
GlobeNewswire·

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network® (NCCN®)